Live feed
Filing
SC 13G
SC 13G0001319244-24-000030·BridgeBio Oncology Therapeutics, Inc.
Schedule 13G ownership disclosure
HELIX ACQUISITION CORP II
Security class unavailable · CUSIP: G4444H101
Event date: 2024-02-09
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 5.0000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001319244-24-000030
- Form type
- SC 13G
- Filer
- BridgeBio Oncology Therapeutics, Inc.
- CIK
- CIK 1869105
- Filed
- Feb 15, 2024
- Reporting period
- Feb 09, 2024
- Description
- Schedule 13G beneficial ownership